PBYI (Puma Biotechnology) Cyclically Adjusted Price-to-FCF: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
53 GF Score
Price $7.80
GF Value $3.34
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Puma Biotechnology  (NAS:PBYI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Puma Biotechnology Cyclically Adjusted Price-to-FCF Related Terms


Puma Biotechnology Cyclically Adjusted Price-to-FCF Historical Data

* Premium members only.

The historical data trend for Puma Biotechnology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Puma Biotechnology Cyclically Adjusted Price-to-FCF Chart

Puma Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Puma Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PBYI vs EVMN, OCGN, EDIT: Cyclically Adjusted Price-to-FCF Comparison

For the Biotechnology subindustry, Puma Biotechnology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Cyclically Adjusted Price-to-FCF falls into.


PBYI
53GF Score
Puma Biotechnology Inc PBYI
Cyclically Adjusted Price-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Puma Biotechnology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Puma Biotechnology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Puma Biotechnology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.303/330.2130*330.2130
=0.303

Current CPI (Mar. 2026) = 330.2130.

Puma Biotechnology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.152 241.018 -1.578
201609 -1.076 241.428 -1.472
201612 -1.163 241.432 -1.591
201703 -0.979 243.801 -1.326
201706 -1.241 244.955 -1.673
201709 -1.480 246.819 -1.980
201712 -2.284 246.524 -3.059
201803 -0.167 249.554 -0.221
201806 -0.472 251.989 -0.619
201809 -0.199 252.439 -0.260
201812 0.183 251.233 0.241
201903 -0.419 254.202 -0.544
201906 1.145 256.143 1.476
201909 -0.188 256.759 -0.242
201912 0.040 256.974 0.051
202003 -0.294 258.115 -0.376
202006 0.406 257.797 0.520
202009 0.043 260.280 0.055
202012 -0.141 260.474 -0.179
202103 0.383 264.877 0.477
202106 -0.002 271.696 -0.002
202109 0.257 274.310 0.309
202112 -0.133 278.802 -0.158
202203 -0.637 287.504 -0.732
202206 -0.306 296.311 -0.341
202209 0.379 296.808 0.422
202212 0.166 296.797 0.185
202303 -0.209 301.836 -0.229
202306 0.068 305.109 0.074
202309 0.221 307.789 0.237
202312 0.217 306.746 0.234
202403 0.233 312.332 0.246
202406 0.021 314.175 0.022
202409 0.224 315.301 0.235
202412 0.316 315.605 0.331
202503 0.071 319.799 0.073
202506 0.280 322.561 0.287
202509 0.190 324.800 0.193
202512 0.280 324.054 0.285
202603 0.303 330.213 0.303

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $7.80 is trading 133.5% above its estimated GF Value™ of $3.34. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Cyclically Adjusted Price-to-FCF:
  • GF Value™: $3.34 vs. price of $7.80 (133.5% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score

Get the complete analysis for PBYI

Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.80
Price
$3.34
GF Value